13F Pro

SEC Form 4 reporting owner

Ra Capital Management, L.P.

Ra Capital Management, L.P. has filed 166 Form 4 transactions reported between December 8, 2025 and September 17, 2026, as a reporting owner of Sionna Therapeutics, Inc., a reporting owner of Tyra Biosciences, Inc., a reporting owner of Artiva Biotherapeutics, Inc., a reporting owner of Vor Biopharma Inc., a reporting owner of Septerna, Inc., a reporting owner of Inhibikase Therapeutics, Inc., a reporting owner of Parabilis Medicines, Inc., a reporting owner of Freenome, Inc., a reporting owner of Climb Bio, Inc., a reporting owner of ARS Pharmaceuticals, Inc., a reporting owner of PepGen Inc., a reporting owner of Acrivon Therapeutics, Inc., a reporting owner of Werewolf Therapeutics, Inc., a reporting owner of Hemab Therapeutics Holdings, Inc., a reporting owner of LENZ Therapeutics, Inc., a reporting owner of Janux Therapeutics, Inc., a reporting owner of Nkarta, Inc., a reporting owner of Bicara Therapeutics Inc., a reporting owner of Acumen Pharmaceuticals, Inc., a reporting owner of Adicet Bio, Inc., a reporting owner of Prelude Therapeutics Inc, a reporting owner of Wave Life Sciences, Inc., a reporting owner of Mineralys Therapeutics, Inc., a reporting owner of Evommune, Inc., a reporting owner of SpyGlass Pharma, Inc. and a reporting owner of Fulcrum Therapeutics, Inc..

Name as filed: RA CAPITAL MANAGEMENT, L.P.

Open-market buys, 24 mo
$485.8M
57 lines
Open-market sales, 24 mo
$162.3M
42 lines
Companies
26
with Form 4 filings
Latest transaction
Sep 17, 2026
transaction date

Roles and reported holdings

  • SIONSionna Therapeutics, Inc.
    Jun 17, 2026 – Sep 17, 2026

    Reporting owner

    Held indirectly (latest line)3,448,812 sh as of Sep 17, 2026 · Form 4

    24 months: $21.8M sold

  • TYRATyra Biosciences, Inc.
    May 28, 2026 – Sep 15, 2026

    Reporting owner

    Held indirectly (latest line)11,616,986 sh as of Sep 15, 2026 · Form 4

    24 months: $200.0M bought

  • ARTVArtiva Biotherapeutics, Inc.
    May 11, 2026 – Sep 10, 2026

    Reporting owner

    Held indirectly (latest line)17,329,570 sh as of Jul 31, 2026 · Form 4

    24 months: $117.6M bought

  • VORVor Biopharma Inc.
    Dec 18, 2025 – Aug 24, 2026

    Reporting owner

    Held indirectly (latest line)4,501,882 sh as of Jul 16, 2026 · Form 4

    24 months: $49.4M sold

  • SEPNSepterna, Inc.
    Jun 26, 2026 – Aug 12, 2026

    Reporting owner

    Held indirectly (latest line)4,777,415 sh as of Aug 12, 2026 · Form 4

    24 months: $31.7M sold

  • IKTInhibikase Therapeutics, Inc.
    Jul 29, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • PBLSParabilis Medicines, Inc.
    Jun 9, 2026 – Jul 22, 2026

    Reporting owner

    Held indirectly (latest line)26,529,686 sh as of Jul 22, 2026 · Form 4

    24 months: $6.9M bought

    2 lines are priced far from PBLS’s market price that day, so the filing may concern a different security. Left out of totals and holdings; see the filings.

  • FRNMFreenome, Inc.
    Jul 20, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • CLYMClimb Bio, Inc.
    Dec 11, 2025 – Jun 29, 2026

    Reporting owner

    Held indirectly (latest line)3,403,429 sh as of Jan 5, 2026 · Form 4

    24 months: $780K bought

  • SPRYARS Pharmaceuticals, Inc.
    Jun 24, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • PEPGPepGen Inc.
    Jun 18, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • ACRVAcrivon Therapeutics, Inc.
    Apr 22, 2026 – Jun 17, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • HOWLWerewolf Therapeutics, Inc.
    May 8, 2026 – Jun 17, 2026

    Reporting owner

    Held indirectly (latest line)303,719 sh as of Jun 17, 2026 · Form 4

    24 months: $964K sold

  • COAGHemab Therapeutics Holdings, Inc.
    May 4, 2026 – Jun 16, 2026

    Reporting owner

    Held indirectly (latest line)6,444,637 sh as of Jun 16, 2026 · Form 4

    24 months: $55.5M bought

  • LENZLENZ Therapeutics, Inc.
    Jun 15, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • JANXJanux Therapeutics, Inc.
    Jun 11, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • NKTXNkarta, Inc.
    Jun 10, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • BCAXBicara Therapeutics Inc.
    Feb 26, 2026 – Jun 9, 2026

    Reporting owner

    Held indirectly (latest line)2,200,000 sh as of Feb 26, 2026 · Form 4

    24 months: $40.0M bought

  • ABOSAcumen Pharmaceuticals, Inc.
    Mar 16, 2026 – Jun 3, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • ACETAdicet Bio, Inc.
    Feb 18, 2026 – Apr 27, 2026

    Reporting owner

    Held indirectly (latest line)1,182,624 sh as of Feb 20, 2026 · Form 4

    24 months: $1.6M bought

  • PRLDPrelude Therapeutics Inc
    Apr 27, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • WVEWave Life Sciences, Inc.
    Mar 26, 2026 – Mar 30, 2026

    Reporting owner

    Held indirectly (latest line)26,975,505 sh as of Mar 30, 2026 · Form 4

    24 months: $54.6M bought

  • MLYSMineralys Therapeutics, Inc.
    Feb 19, 2026 – Mar 30, 2026

    Reporting owner

    Held indirectly (latest line)5,825,521 sh as of Mar 30, 2026 · Form 4

    24 months: $8.8M bought

  • EVMNEvommune, Inc.
    Feb 17, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • SGPSpyGlass Pharma, Inc.
    Feb 5, 2026 – Feb 9, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

    2 lines are priced far from SGP’s market price that day, so the filing may concern a different security. Left out of totals and holdings; see the filings.

  • FULCFulcrum Therapeutics, Inc.
    Dec 8, 2025

    Reporting owner

    Held indirectly (latest line)6,053,960 sh as of Dec 8, 2025 · Form 4

    24 months: $58.4M sold

Transaction history

All 166 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Sep 17, 2026SIONOpen-market saleCode S · indirect33,800$252K@ $7.46Form 4
Sep 17, 2026SIONOpen-market saleCode S · indirect3,415,011$21.6M@ $6.32Form 4
Sep 15, 2026TYRAOpen-market purchaseCode P · indirect9,078,529$200.0M@ $22.03Form 4
Sep 10, 2026ARTVGrant or awardCode A · indirect16,250—Form 4
Sep 8, 2026ARTVGrant or awardCode A · indirect13,750—Form 4
Aug 24, 2026VOROption exerciseCode M · indirect1,500$6K@ $3.74Form 4
Aug 12, 2026SEPNOpen-market saleCode S · indirect746,500$31.7M@ $42.50Form 4
Jul 31, 2026ARTVOpen-market purchaseCode P · indirect24,944$248K@ $9.93Form 4
Jul 29, 2026ARTVOpen-market purchaseCode P · indirect20,824$208K@ $9.99Form 4
Jul 29, 2026IKTOther acquisition or dispositionCode J · indirect18,030,000—Form 4
Jul 24, 2026ARTVOpen-market purchaseCode P · indirect41,319$413K@ $9.99Form 4
Jul 23, 2026ARTVOpen-market purchaseCode P · indirect59,880$596K@ $9.96Form 4
Jul 22, 2026ARTVOpen-market purchaseCode P · indirect84,124$835K@ $9.93Form 4
Jul 22, 2026PBLSOpen-market purchaseCode P · indirect47,250$1.4M@ $29.77Form 4
Jul 21, 2026ARTVOpen-market purchaseCode P · indirect120,582$1.2M@ $9.55Form 4
Jul 21, 2026PBLSOpen-market purchaseCode P · indirect37,723$1.1M@ $30.00Form 4
Jul 21, 2026PBLSOpen-market purchaseCode P · indirect6,504$190K@ $29.17Form 4
Jul 21, 2026PBLSOpen-market purchaseCode P · indirect21,696$607K@ $27.96Form 4
Jul 20, 2026FRNMGrant or awardCode A · indirect336,965$3.4M@ $10.00Form 4
Jul 20, 2026FRNMGrant or awardCode A · indirect4,918,411$49.2M@ $10.00Form 4
Jul 20, 2026FRNMGrant or awardCode A · indirect367,427—Form 4
Jul 20, 2026FRNMGrant or awardCode A · indirect908,103—Form 4
Jul 20, 2026FRNMGrant or awardCode A · indirect553,703—Form 4
Jul 20, 2026FRNMGrant or awardCode A · indirect970,950—Form 4
Jul 20, 2026FRNMGrant or awardCode A · indirect6,561,711—Form 4
Jul 20, 2026PBLSOpen-market purchaseCode P · indirect32,987$914K@ $27.72Form 4
Jul 20, 2026PBLSOpen-market purchaseCode P · indirect98,433$2.7M@ $27.13Form 4
Jul 17, 2026ARTVOpen-market purchaseCode P · indirect7,882$71K@ $8.95Form 4
Jul 16, 2026VOROpen-market saleCode S · indirect213$4K@ $19.75Form 4
Jul 16, 2026VOROption exerciseCode X · indirect2,100,000$4K@ $0.0020Form 4
Jul 16, 2026ARTVOpen-market purchaseCode P · indirect152,472$1.4M@ $8.93Form 4
Jul 13, 2026ARTVOpen-market purchaseCode P · indirect6,552$59K@ $8.94Form 4
Jul 10, 2026ARTVOpen-market purchaseCode P · indirect15,102$135K@ $8.97Form 4
Jun 29, 2026CLYMGrant or awardCode A · indirect70,284—Form 4
Jun 26, 2026ARTVOpen-market purchaseCode P · indirect1,876$17K@ $8.98Form 4
Jun 26, 2026SEPNGrant or awardCode A · indirect15,000—Form 4
Jun 25, 2026ARTVOpen-market purchaseCode P · indirect31,000$275K@ $8.88Form 4
Jun 24, 2026SPRYGrant or awardCode A · indirect30,000—Form 4
Jun 18, 2026PEPGGrant or awardCode A · indirect34,000—Form 4
Jun 17, 2026ACRVGrant or awardCode A · indirect20,275—Form 4
Jun 17, 2026HOWLOpen-market saleCode S · indirect27,695$10K@ $0.3500Form 4
Jun 17, 2026HOWLOpen-market saleCode S · indirect389,216$136K@ $0.3500Form 4
Jun 17, 2026SIONGrant or awardCode A · indirect17,340—Form 4
Jun 16, 2026ARTVOpen-market purchaseCode P · indirect124,893$1.1M@ $8.89Form 4
Jun 16, 2026COAGOpen-market purchaseCode P · indirect61,523$1.5M@ $24.98Form 4
Jun 16, 2026HOWLOpen-market saleCode S · indirect9,939$4K@ $0.3700Form 4
Jun 16, 2026HOWLOpen-market saleCode S · indirect139,686$52K@ $0.3700Form 4
Jun 15, 2026ARTVOpen-market purchaseCode P · indirect15,414$139K@ $8.99Form 4
Jun 15, 2026COAGOpen-market purchaseCode P · indirect6,146$153K@ $24.89Form 4
Jun 15, 2026HOWLOpen-market saleCode S · indirect8,554$3K@ $0.3900Form 4
Jun 15, 2026HOWLOpen-market saleCode S · indirect120,216$47K@ $0.3900Form 4
Jun 15, 2026LENZGrant or awardCode A · indirect22,100—Form 4
Jun 12, 2026ARTVOpen-market purchaseCode P · indirect391,019$3.4M@ $8.57Form 4
Jun 12, 2026HOWLOpen-market saleCode S · indirect11,322$5K@ $0.4000Form 4
Jun 12, 2026HOWLOpen-market saleCode S · indirect159,119$64K@ $0.4000Form 4
Jun 11, 2026PBLSConversion of derivativeCode C · indirect1,666,829—Form 4
Jun 11, 2026PBLSConversion of derivativeCode C · indirect9,445,363—Form 4
Jun 11, 2026PBLSConversion of derivativeCode C · indirect160,562—Form 4
Jun 11, 2026PBLSConversion of derivativeCode C · indirect642,250—Form 4
Jun 11, 2026PBLSOpen-market purchaseCode P · indirectPrice far from market; may be another security1,460,397$29.2M@ $20.00Form 4
Jun 11, 2026PBLSOpen-market purchaseCode P · indirectPrice far from market; may be another security19,728,353$394.6M@ $20.00Form 4
Jun 11, 2026PBLSConversion of derivativeCode C · indirect1,187,881—Form 4
Jun 11, 2026PBLSConversion of derivativeCode C · indirect6,556,740—Form 4
Jun 11, 2026ARTVOpen-market purchaseCode P · indirect548,580$4.3M@ $7.91Form 4
Jun 11, 2026JANXGrant or awardCode A · indirect15,500—Form 4
Jun 11, 2026JANXGrant or awardCode A · indirect5,500—Form 4
Jun 11, 2026VORGrant or awardCode A · indirect57,162—Form 4
Jun 11, 2026HOWLOpen-market saleCode S · indirect17,437$7K@ $0.3800Form 4
Jun 11, 2026HOWLOpen-market saleCode S · indirect245,066$93K@ $0.3800Form 4
Jun 10, 2026ARTVOpen-market purchaseCode P · indirect103$721@ $7.00Form 4
Jun 10, 2026HOWLOpen-market saleCode S · indirect3,051$1K@ $0.3700Form 4
Jun 10, 2026HOWLOpen-market saleCode S · indirect42,872$16K@ $0.3700Form 4
Jun 10, 2026NKTXGrant or awardCode A · indirect37,000—Form 4
Jun 9, 2026PBLSGrant or awardCode A · indirect20,215—Form 4
Jun 9, 2026ARTVOpen-market purchaseCode P · indirect479,039$3.3M@ $6.91Form 4
Jun 9, 2026BCAXGrant or awardCode A · indirect19,475—Form 4
Jun 9, 2026HOWLOpen-market saleCode S · indirect24,565$9K@ $0.3700Form 4
Jun 9, 2026HOWLOpen-market saleCode S · indirect345,235$128K@ $0.3700Form 4
Jun 5, 2026CLYMGrant or awardCode A · indirect40,000—Form 4
Jun 3, 2026ABOSGrant or awardCode A · indirect53,250—Form 4
Jun 3, 2026ABOSGrant or awardCode A · indirect35,500—Form 4
May 28, 2026TYRAGrant or awardCode A · indirect13,160—Form 4
May 20, 2026COAGOpen-market purchaseCode P · indirect996$25K@ $24.94Form 4
May 19, 2026COAGOpen-market purchaseCode P · indirect3,802$95K@ $24.97Form 4
May 18, 2026ACRVGrant or awardCode A · indirect9,366—Form 4
May 12, 2026COAGOpen-market purchaseCode P · indirect6,387$159K@ $24.90Form 4
May 12, 2026HOWLOpen-market saleCode S · indirect6,719$4K@ $0.6400Form 4
May 12, 2026HOWLOpen-market saleCode S · indirect94,432$60K@ $0.6400Form 4
May 11, 2026ARTVOpen-market purchaseCode P · indirect2,170,138$25.0M@ $11.52Form 4
May 11, 2026ARTVOpen-market purchaseCode P · indirect6,510,416$75.0M@ $11.52Form 4
May 11, 2026COAGOpen-market purchaseCode P · indirect25,720$643K@ $25.00Form 4
May 11, 2026COAGOpen-market purchaseCode P · indirect14,149$346K@ $24.47Form 4
May 11, 2026HOWLOpen-market saleCode S · indirect5,812$4K@ $0.6700Form 4
May 11, 2026HOWLOpen-market saleCode S · indirect81,678$55K@ $0.6700Form 4
May 8, 2026COAGOpen-market purchaseCode P · indirect1,483$37K@ $24.98Form 4
May 8, 2026HOWLOpen-market saleCode S · indirect25,012$18K@ $0.7100Form 4
May 8, 2026HOWLOpen-market saleCode S · indirect351,514$250K@ $0.7100Form 4
May 7, 2026COAGOpen-market purchaseCode P · indirect1,985$50K@ $24.95Form 4
May 7, 2026COAGOpen-market purchaseCode P · indirect7,921$193K@ $24.34Form 4
May 6, 2026COAGOpen-market purchaseCode P · indirect53,407$1.3M@ $24.83Form 4
May 6, 2026COAGOpen-market purchaseCode P · indirect14,611$347K@ $23.77Form 4
May 5, 2026COAGOpen-market purchaseCode P · indirect10,268$257K@ $25.00Form 4
May 5, 2026COAGOpen-market purchaseCode P · indirect87,143$2.1M@ $24.59Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect10,054—Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect56,972—Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect18,146—Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect42,341—Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect27,720—Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect64,680—Form 4
May 4, 2026COAGOpen-market purchaseCode P · indirect133,750$2.4M@ $18.00Form 4
May 4, 2026COAGOpen-market purchaseCode P · indirect2,541,250$45.7M@ $18.00Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect221,188—Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect1,009,052—Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect3,607,846—Form 4
Apr 29, 2026CLYMGrant or awardCode A · indirect2,106,000$20.0M@ $9.50Form 4
Apr 27, 2026ACETOther acquisition or dispositionCode J · indirect250,000—Form 4
Apr 27, 2026PRLDOther acquisition or dispositionCode J · indirect1,407,000—Form 4
Apr 22, 2026VOROpen-market saleCode S · indirect165,150$2.6M@ $15.77Form 4
Apr 22, 2026ACRVGrant or awardCode A · indirect3,888,888$7.0M@ $1.80Form 4
Apr 20, 2026VOROpen-market saleCode S · indirect171,963$2.7M@ $15.77Form 4
Apr 17, 2026VOROpen-market saleCode S · indirect458,411$7.5M@ $16.28Form 4
Apr 15, 2026VOROpen-market saleCode S · indirect53,644$859K@ $16.01Form 4
Apr 14, 2026VOROpen-market saleCode S · indirect153,735$2.5M@ $15.97Form 4
Apr 13, 2026VOROpen-market saleCode S · indirect530,610$8.6M@ $16.15Form 4
Apr 10, 2026VOROpen-market saleCode S · indirect828$13K@ $15.75Form 4
Apr 9, 2026VOROpen-market saleCode S · indirect135,201$2.2M@ $16.59Form 4
Apr 8, 2026VOROpen-market saleCode S · indirect130,862$2.2M@ $16.91Form 4
Apr 8, 2026VOROpen-market saleCode S · indirect353,242$5.8M@ $16.32Form 4
Apr 6, 2026VOROpen-market saleCode S · indirect6,775$125K@ $18.50Form 4
Apr 6, 2026VOROpen-market saleCode S · indirect44,728$774K@ $17.31Form 4
Apr 6, 2026VOROpen-market saleCode S · indirect537,754$8.9M@ $16.51Form 4
Apr 2, 2026VOROpen-market saleCode S · indirect1,525$29K@ $19.06Form 4
Apr 2, 2026VOROpen-market saleCode S · indirect258,475$4.7M@ $18.23Form 4
Mar 30, 2026WVEOpen-market purchaseCode P · indirect971,091$6.3M@ $6.50Form 4
Mar 30, 2026MLYSOpen-market purchaseCode P · indirect58,300$1.4M@ $24.16Form 4
Mar 27, 2026WVEOpen-market purchaseCode P · indirect2,495,623$16.0M@ $6.43Form 4
Mar 27, 2026MLYSOpen-market purchaseCode P · indirect310,700$7.4M@ $23.67Form 4
Mar 26, 2026WVEOpen-market purchaseCode P · indirect351,224$2.2M@ $6.38Form 4
Mar 26, 2026WVEOpen-market purchaseCode P · indirect4,954,558$30.0M@ $6.06Form 4
Mar 16, 2026ABOSGrant or awardCode A · indirect6,060,606$20.0M@ $3.30Form 4
Feb 26, 2026BCAXOpen-market purchaseCode P · indirect2,200,000$35.2M@ $16.00Form 4
Feb 26, 2026BCAXOpen-market purchaseCode P · indirect300,000$4.8M@ $16.00Form 4
Feb 20, 2026ACETOpen-market purchaseCode P · indirect74,751$543K@ $7.27Form 4
Feb 19, 2026ACETOpen-market purchaseCode P · indirect74,268$535K@ $7.21Form 4
Feb 19, 2026MLYSGrant or awardCode A · indirect8,300—Form 4
Feb 19, 2026MLYSGrant or awardCode A · indirect6,200—Form 4
Feb 18, 2026ACETOpen-market purchaseCode P · indirect74,577$525K@ $7.04Form 4
Feb 17, 2026EVMNGrant or awardCode A · indirect35,868$1000K@ $27.88Form 4
Feb 9, 2026SGPConversion of derivativeCode C · indirect272,056—Form 4
Feb 9, 2026SGPConversion of derivativeCode C · indirect222,591—Form 4
Feb 9, 2026SGPConversion of derivativeCode C · indirect767,294—Form 4
Feb 9, 2026SGPConversion of derivativeCode C · indirect1,150,941—Form 4
Feb 9, 2026SGPOpen-market purchaseCode P · indirectPrice far from market; may be another security248,034$4.0M@ $16.00Form 4
Feb 9, 2026SGPOpen-market purchaseCode P · indirectPrice far from market; may be another security3,441,966$55.1M@ $16.00Form 4
Feb 9, 2026SGPConversion of derivativeCode C · indirect1,806,644—Form 4
Feb 9, 2026SGPConversion of derivativeCode C · indirect2,524,473—Form 4
Feb 5, 2026SGPGrant or awardCode A · indirect27,400—Form 4
Jan 5, 2026CLYMOpen-market purchaseCode P · indirect7,111$25K@ $3.50Form 4
Dec 18, 2025VORGrant or awardCode A · indirect3,000—Form 4
Dec 18, 2025VORGrant or awardCode A · indirect4,625,346$50.0M@ $10.81Form 4
Dec 12, 2025CLYMOpen-market purchaseCode P · indirect101,462$290K@ $2.86Form 4
Dec 11, 2025CLYMOpen-market purchaseCode P · indirect213,099$465K@ $2.18Form 4
Dec 11, 2025CLYMDisposition to issuerCode D · indirect20,440,000—Form 4
Dec 8, 2025FULCOpen-market saleCode S · indirect91,722$1.4M@ $14.98Form 4
Dec 8, 2025FULCOpen-market saleCode S · indirect2,706,397$38.6M@ $14.28Form 4
Dec 8, 2025FULCOpen-market saleCode S · indirect1,377,020$18.4M@ $13.33Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

4 open-market lines are priced outside 0.67×–1.5× of the stock’s closing price that day. A gap that large usually means the filing reports a different security than the company it is filed under, so those lines are shown but left out of totals and holdings.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.